Ocimum Biosolutions has bagged a US Patent via No US 7,415,358 B2 for the 'molecular toxicology modelling' capabilities. The patent describes elucidation of the global changes in gene expression and identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes can be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with micro arrays and other solid-phase probes.
Ocimum Biosolutions CEO Anu Acharya said, "We have consistently been in the forefront of Genomics Innovation over many years and this patent reiterates our strong commitment to continue as a leader in this space."
"Ocimum Biosolutions and its subsidiary company Gene Logic will continue to innovate through areas like Genotyping, Gene Expression, PCR and other data validation approaches to bring the latest and most promising technologies to our pharmaceutical and biotech clients who have chosen us as their preferred partner in their discovery pursuit for more than a decade," added Acharya.
As a leading integrated genomics company, Ocimum, provides comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant micro-array services and essential research consumables. Over two thirds of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen Ocimum as their preferred outsourcing partner and utilize Ocimum's expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.
Gene Logic is a preferred outsourcing partner for providing integrated bio-repository and genomic services for several global pharmaceutical companies. The company's global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification.
In creating the world's largest commercial gene expression databases - BioExpress and ToxExpress, Gene Logic has expertise and capabilities that are unparalleled in the genomic services industry. It provides multiple GLP-compliant platforms for gene expression and SNP genotyping data generation, full bio-repository and genomic services support for the Genetic Alliance, which is an umbrella organization representing ~600 genetic advocacy groups. Besides providing the physical infrastructure for storing thousands of biological samples, Gene Logic provides services to assist sample accrual, IRB approvals, CRO training, sample collection, clinical data capture and management.